National Health Planning and Resources Development Act

mPulse Recognizes Innovative Healthcare Organizations in the Sixth Annual Activate 2023 Awards

Retrieved on: 
Tuesday, October 31, 2023
Data Management, Medical Supplies, Technology, General Health, Telemedicine, Virtual Medicine, Mobile, Wireless, Apps, Applications, Consumer, Pharmaceutical, Mental Health, Medical Devices, Baby, Maternity, Health Technology, Hospitals, Dental, Other Technology, Artificial Intelligence, Software, Health, Internet, Knowledge, SMS, Education, OB, PHI, Emergency department, Blood pressure, SME, Habit, UnitedHealth Group, MEDLINE, Digital technology, L.A, RVO, Diabetes, Mother, COVID, Health equity, Red Ventures, National Health Planning and Resources Development Act, Medicaid, AI, Patient, L.A. Care Health Plan, Activate, Urban Health Resource Centre, Pharmaceutical industry, Nursing, Health insurance, Mobile phone, Latinx

mPulse , the leader in conversational AI and digital engagement solutions for the healthcare industry, announced the winners of the Activate 2023 Awards.

Key Points: 
  • mPulse , the leader in conversational AI and digital engagement solutions for the healthcare industry, announced the winners of the Activate 2023 Awards.
  • The awards recognize key customers and healthcare organizations who showcase industry-leading health outcomes, technology innovation, and health equity results for members.
  • The winners were announced at mPulse’s annual Activate conference where industry leaders and SMEs share innovative strategies for digital health activation to over 200 participants across the healthcare ecosystem.
  • Activate Award participants include healthcare industry leaders and innovative health plans focused on improving patient outcomes, incorporating behavioral science into member journey design, and addressing other critical engagement goals.

New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82%

Retrieved on: 
Friday, August 19, 2022
Woman, JD, National Medical Products Administration, III, Ageing, Laboratory, Genetic testing, SEHK, CEO, Cervical cancer, Diagnosis, Clinical trial, Cancer, Policy, Hospital, Pain, Urine, Research, Attention, Compliance, Squamous cell carcinoma, ZHU, ISO9001, Prostate Cancer Foundation, Marketing, COVID-19, Company, National Health Planning and Resources Development Act, NGS, Awareness, Stomach, Technopolis, FIT, Technology, Helicobacter pylori, ISO13485, Science, Circle, Liver cancer, Insurance, Pharmacy, Colorectal cancer, Logic, HPV, Pharmaceutical industry, Film, Tmall

The Company announced its cervical cancer screening product, CerviClear(TM), which had been launched in a large-scale prospective multi-center registered clinical trial in June 2022.

Key Points: 
  • The Company announced its cervical cancer screening product, CerviClear(TM), which had been launched in a large-scale prospective multi-center registered clinical trial in June 2022.
  • The Company's revenue in the first half of the year has exceeded last year's full-year revenue.
  • As of June 30, 2022, the gross margin of ColoClear reached 75.7%, the gross margin of Pupu Tube reached 80.0% and the gross margin of UU Tube reached 90.0%.
  • New Horizon Health works extensively with hundreds of hospitals, health check-ups, insurance companies, pharmacies and online channels.

Kaixin Auto Holdings Announces Intention Order for 5,000 Electric Vehicles for Health Services

Retrieved on: 
Tuesday, August 16, 2022
U.S. Securities and Exchange Commission, Cell, Industry, Forward-looking statement, GLOBE, Growth, SEC, Healthy Village, National Health Planning and Resources Development Act, RMB, Partnership, NASDAQ, Intention, Science, Cell engineering, Goal, Private Securities Litigation Reform Act, Conditional sentence, National Association Medical Staff Services, Annual report, Mining, Terminology, USD, Kaixin001

The total amount of this intention order is about RMB 2 billion (equivalent to USD$295 million).

Key Points: 
  • The total amount of this intention order is about RMB 2 billion (equivalent to USD$295 million).
  • Its business mainly involves routine physical examinations, chronic disease screening, and other public health services.
  • The medical vehicles ordered from Kaixin will be mounted with intelligent testing equipment that provides high mobility to its medical staff to collect and process medical data that would be integrated into the national health system.
  • Kaixin Auto Holdings is one of the primary dealership networks in the premium used car segment and new car sales in China.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

United Kingdom Crane Market Assessment & Forecast 2021-2027 - Rise in Construction Activities in Health Care and Clean Energy Projects - ResearchAndMarkets.com

Retrieved on: 
Monday, November 1, 2021
Construction & Property, Other Construction & Property, HS2, FDI, National Health Planning and Resources Development Act, Adoption, Original equipment manufacturer, Government, Construction, IOT, Crane, Data analysis, Renting, Warehouse

The "United Kingdom Crane Market - Strategic Assessment & Forecast 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United Kingdom Crane Market - Strategic Assessment & Forecast 2021-2027" report has been added to ResearchAndMarkets.com's offering.
  • The United Kingdom crane market is expected to show an incremental growth of 1,519 units during the forecast period.
  • The rise in construction activities in health care and clean energy projects will drive the demand for cranes in the UK.
  • Cranes used in the construction industry accounted for the largest market share, pertaining to large government expenditure on construction projects.